Adalimumab is suitable for everyday use;Adalimumab erweist sich als alltagstauglich

Pharmazeutische Zeitung

Volumn 149, Issue 26, 2004, Pages

  Becker, Conny ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADD ON THERAPY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; NOTE; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYMPTOM;

EID: 3142653757     PISSN: 00317136     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (0)